Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 408Observational 5Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

3-Iodobenzylguanidine 6Magnetic Resonance Spectroscopy 5Amifampridine 5gallium 68 PSMA-11 4fludarabine phosphate 3Cyclophosphamide 3pembrolizumab 2fluorodopa F 18 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Oxaliplatin 2Ga(III)-DOTATOC 2Fluorouracil 2Bortezomib 2Bone Marrow Transplantation 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1motexafin gadolinium 1mifamurtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Expanded_access × Everolimus × Clear all
NCT03493152 2025-05-28

Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

The University of Texas Health Science Center at San Antonio

No longer available
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡